Search

INVESTIGATION OF PLGA NANOPARTICLES IN CONJUNCTION WITH NUCLEAR LOCALIZATION SEQUENCE FOR ENHANCED DELIVERY OF ANTIMIR PHOSPHOROTHIOATES IN CANCER CELLS IN VITRO

Numerous first generation phosphorothioates and their derivatives have shown promise targeting mRNA for therapeutic applications and...

Xconomy's Seattle Event to Explore Tech Convergence in Life Sciences

XCONOMY'S SEATTLE EVENT TO EXPLORE TECH CONVERGENCE IN LIFE SCIENCES

The lines between biotech and high tech are blurring, and Seattle is one of the country's hotspots for this convergence. IT innovations...

 
 
 

POSEIDA TO ADVANCE CAR-T FOR MYELOMA WITH NOVARTIS-LED $142M ROUND

The race to bring CAR-T cell therapy to multiple myeloma, a persistent and deadly cancer of the bone marrow, continued on Monday with...

CAR-T MAKER POSEIDA FORGOES IPO, HAULS IN $142M SERIES C INSTEAD

CAR-T developer Poseida Therapeutics has put the kibosh on its IPO plans for now and is settling instead for a $142 million series...

 
 
 
Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs

ARRAKIS SPICES UP DEVELOPMENT EFFORTS WITH $75M SERIES B ROUND FOR RNA-TARGETING DRUGS

The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting...

Bio Roundup: Nationwide's Rise, a Surgeon's Quest, CRISPR USA & More

BIO ROUNDUP: NATIONWIDE'S RISE, A SURGEON'S QUEST, CRISPR USA & MORE

Persistence and perseverance were the themes of two of our top stories this week. First there's the story of Nationwide Children's...

 
 
 
 
 
 
Turning Point Prices IPO, Raising $166M to Test Cancer Drugs

TURNING POINT PRICES IPO, RAISING $166M TO TEST CANCER DRUGS

Turning Point Therapeutics raised more than $166 million in its IPO, pricing at the top of its range and putting nearly 2 million more...

A startup just raised $27 million to make a new kind of painkiller using technology from Harvard scientists, as the race to replace opioids heats up

A STARTUP JUST RAISED $27 MILLION TO MAKE A NEW KIND OF PAINKILLER USING TECHNOLOGY FROM HARVARD SCIENTISTS, AS THE RACE TO REPLACE OPIOIDS HEATS UP

America is in the midst of a deadly opioid epidemic. There's a need for better pain drugs that aren't addictive. A new startup, Nocion...

 
 
 

ALNYLAM INITIATES ILLUMINATE-B PHASE 3 PEDIATRIC STUDY OF LUMASIRAN FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 AND PRESENTS NEW POSITIVE RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY

CAMBRIDGE, Mass.--Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that the Company has initiated...

 
 
 
How an Ohio Kids' Hospital Quietly Became Ground Zero for Gene Therapy

HOW AN OHIO KIDS' HOSPITAL QUIETLY BECAME GROUND ZERO FOR GENE THERAPY

If a once-modest regional hospital and its new biotech allies have their way, the capital of Ohio could one day rival America's other...

PRACTICE ACCOUNT MANAGER - AIMMUNE THERAPEUTICS - SAN DIEGO, CA

Headquartered in Brisbane, California - the heart of San Francisco's biotechnology hub - Aimmune has additional offices in London and...

 
 
 

ENGINEERED SKIN TISSUE EQUIVALENTS FOR PRODUCT EVALUATION AND THERAPEUTIC APPLICATIONS

Abstract This article reviews the current status of skin tissue equivalents that have emerged as relevant tools in commercial and therapeutic...

Novel Molecule May Help Fight Type 2 Diabetes, Non-alcoholic Fatty Liver Disease

NOVEL MOLECULE MAY HELP FIGHT TYPE 2 DIABETES, NON-ALCOHOLIC FATTY LIVER DISEASE

New molecule EPB-53 could lead to new therapeutic strategies to treat non-alcoholic fatty liver disease and type 2 diabetes, finds...

 
 
 
Sobriety Pays: DynamiCare Gamifies Staying Clean for Recovering Addicts

SOBRIETY PAYS: DYNAMICARE GAMIFIES STAYING CLEAN FOR RECOVERING ADDICTS

Eric Gastfriend was looking for his next tech startup idea after leaving his video game startup Happy Cloud and finishing an MBA at...

The incredible Roman bathhouse that was built over 2,000 years ago and is still running today 

THE INCREDIBLE ROMAN BATHHOUSE THAT WAS BUILT OVER 2,000 YEARS AGO AND IS STILL RUNNING TODAY 

Hammam Essalihine in Khenchela, Algeria, dates back to the time of the Flavian Dynasty and its waters are touted as having 'therapeutic...

 
 
 

TURNING POINT THERAPEUTICS APPOINTS ANNETTE NORTH AS EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL

SAN DIEGO--Turning Point Therapeutics, Inc., a clinical-stage precision oncology company developing novel drugs that address treatment...